Skip to main content

Table 1 Failed, rejected, and reanalysed samples in the comparison of the PyroMark and TheraScreen K-RAS assays

From: KRAS analysis in colorectal carcinoma: Analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice

DNA # PyroMark TheraScreen Comments
21 ND ND Pyro: Failed, repeated twice. DxS: Rejected, control Ct > 35
25 WT ND Pyro: Check, triplicate = wt. DxS: Rejected, control Ct > 35
30 WT ND Pyro: Check, triplicate = wt. DxS: Rejected, control Ct > 35
37 ND ND Pyro: Check, triplicate = inconclusive. DxS: Rejected, control Ct > 35
54 WT 12 GTT Pyro: Triplicate = wt. DxS: 12 GTT mutation
61 WT ND DxS: Rejected, control Ct > 35
64 ND ND Pyro: Failed. DxS: Rejected, control Ct > 35
66 12 GAT ND Pyro: Check, triplicate = 12 GAT mutation. DxS: Rejected, control Ct > 35
67 ND ND Pyro: Failed, repeated in triplicate. DxS: Rejected, control Ct > 35
89 ND ND Pyro: Failed. DxS: Rejected, control Ct > 35
93 ND WT Pyro: Check, triplicate = inconclusive. DxS: triplicate = wt
100 12 GTT 12 GTT Pyro: Low mutation signal, triplicate = 12 GTT mutation. DxS: 12 GTT mutation
  1. Summary of the mutational status of samples with "check", "failed" (PyroMark) or "rejected" (TheraScreen, DxS) status. ND = mutation status could not be determined.